Citations

Clear

16280 citation(s) found for "Yu, David".

State-of-the-Art Review of Current Technology in Pressure Injury Early Detection
Bogie, Kath M. , Sonenblum, Sharon Eve , Newton, David , Vargo, Deanna M., Ronin, Jamie, Hester, Amy , Gillespie, Carroll, Tescher, Ann, Iyer, Vignesh , Brienza, David M. , Tzen, Yi-Ting , Delmore, Barbara , M Bogie, Kath , Sonenblum, Sharon Eve , Newton, David , Iyer, Vignesh , Brienza, David , Delmore, Barbara

Mayo Clinic

Advances in Skin & Wound Care | October 14, 2025 | Volume: 38 | Issue: 10 | Pages: E128-E137

10.1097/asw.0000000000000358 | PMID 41085249 Get It

OBJECTIVE: To review currently available devices on pressure injury (PI) early detection, summarize challenges and opportunities to clinical implementation, and propose evaluation standards for device categories. DATA SOURCES: PubMed and US Food and Drug Administration (FDA) databases. STUDY SELECTION: Published in English from peer-reviewed journals with full text available. Excluded if opinion statements, lack of empirical data, or unrelated to project’s objective. DATA EXTRACTION: For both clinical device and research equipment: measurement mechanisms, measurement types, outcome/output, FDA classification, and indications for use. Addition data were extracted for clinical devices: instruction for use, end user, order requirement, and billable code. DATA SYNTHESIS: The 4 clinical devices are ultrasound, long-wave infrared thermography, subepidermal moisture assessment, and nearinfrared spectroscopy. The 3 research devices are laser Doppler flowmetry, laser speckle contrast imaging, and colorimetry. CONCLUSIONS: The measurement mechanisms of all devices are unique and different from each other. One commonality is that they could measure the nonvisual signs of PI (eg, inflammation, edema, ischemia, and hypoxia) except colorimeter. Some clinical devices are promising to assist with early identification of PIs, especially in individuals with dark skin tones. Currently, there is no reimbursement available for early detection of PI. Current evidence did not support replacing the standard skin assessment of visual inspection and palpation with the devices reviewed, rather using validated devices to augment the current practice standard. This is especially recommended for individuals identified as high risk for a PI on admission to a facility.
Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
Lima, Gabriel Paiva da Silva , Rao, Renata, Szklener, Sebastian , Tassorelli, Cristina , Nastaj, Marcin, Chou, Denise E. , Khodavirdi, Ani C., Chehrenama, Mahan, Zhu, Yineng, Bhatia, Ajay, Lima, Gabriel Paiva da Silva , Dodick, David W , Szabó, Gyöngyi, Nastaj, Marcin, Zhu, Yineng, Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 14, 2025 | Volume: 66 | Issue: 3 | Pages: 658-671

10.1111/head.15071 | PMID 41084999 Get It

Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not fully capture the holistic benefit of the therapy. Erenumab, a monoclonal antibody targeting the calcitonin gene–related peptide pathway, has demonstrated reduction in monthly migraine days and improvement in function in patients with episodic and chronic migraine. Methods In this phase 4, interventional, double‐blind, randomized, placebo‐controlled, multicenter, global study, treatment with erenumab was assessed over 4 months in adults with high‐frequency episodic migraine. The study was conducted at 61 sites located across North America and Europe between September 2020 and October 2023. Patients with ≥1 qualifying oral triptan‐treated migraine attack at baseline were randomized to receive erenumab 140 mg or placebo subcutaneously once monthly. The primary endpoint was change from baseline in mean monthly hours of at least moderate headache pain intensity over months 1, 2, and 3; secondary endpoints included change from baseline in mean monthly function, mean monthly duration of at least moderate pain intensity in migraine attacks, and mean monthly peak migraine pain intensity. Safety outcomes were also assessed. Results Of 512 randomized patients, 510 received erenumab 140 mg ( n = 254) or placebo ( n = 256) once monthly. Demographics and baseline characteristics were balanced between the two treatment arms. Erenumab 140 mg was superior to placebo in reducing duration of moderate or severe headache pain intensity over months 1, 2, and 3 (least squares mean [95% confidence interval {CI}] difference, −7.95 [−11.45, −4.46]; p < 0.001). Compared with placebo, erenumab significantly reduced migraine functional impact as assessed by the four domains of the Migraine Functional Impact Questionnaire, with a least squares mean (95% CI) difference of −7.36 (−10.80, −3.92) for physical functioning, −7.10 (−10.34, −3.87) for usual activities, −6.82 (−10.37, −3.27) for social functioning, and − 7.05 (−10.76, −3.34) for emotional functioning ( p < 0.001 for all domains). Significant reductions with erenumab compared with placebo were also observed in duration of at least moderate pain intensity in residual or break‐through migraine attacks (least squares mean [95% CI] difference, −1.07 [−1.92, −0.22]; p = 0.013) and peak migraine pain intensity (−0.48 [−0.85, −0.11]; p = 0.011). Incidence of grade 3 adverse events was 1.6% with erenumab and 1.2% with placebo; no grade 4 or fatal adverse events were reported in either treatment arm. Conclusion Findings from the EMBRACE study demonstrated that treatment with erenumab in patients with high‐frequency episodic migraine can provide positive therapeutic effects on ictal burden and pain, with residual migraine attacks tending to be shorter and less painful, with less overall impact.
Predictors of Permanent Pacemaker Implantation Following Valve‐in‐Valve Transcatheter Aortic Valve Replacement
Quelal, Karol , Arya, Namrata , Sugrue, Alan , Cha, Yong‐Mei , Mackram, Eleid F, Deshmukh, Abhishek , Quelal, Karol , Donisan, Teodora , Harmon, David , Sugrue, Alan , Cha, Yong-Mei , Deshmukh, Abhishek J , Alkhouli, Mohamad

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 14, 2025 | Volume: 36 | Issue: 12 | Pages: 3299-3309

10.1111/jce.70139 | PMID 41084173 Get It

ABSTRACT Background Valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR) is increasingly used to treat structural valve degeneration. Permanent pacemaker implantation (PPI) following TAVR is associated with increased morbidity and mortality, yet predictors specific to ViV‐TAVR remain poorly defined. Objective To identify clinical and procedural predictors of PPI in patients undergoing ViV‐TAVR. Methods We conducted a retrospective observational study of consecutive ViV‐TAVR cases at the Mayo Clinic from 2012 to 2022. Clinical, ECG, procedural data and fluoroscopic measurements were analyzed, and propensity score matching was used to adjust for confounding. Predictors of PPI were identified using multivariable logistic regression. Results Among 261 patients, 24 (9.2%) underwent PPI. Balloon‐expandable valves were used in 66.7% and self‐expanding valves in 33.3%. Predictors of PPI included Preprocedural bifascicular block (OR 12.15, 95% CI: 2.52–68.89, p = 0.003), greater septal implantation depth (OR 1.29, 95% CI: 1.04–1.65, p = 0.019), and post‐procedural new left (OR 23.56, 95% CI: 4.91–48.52, p = 0.0004) and right bundle branch blocks (OR 24.4, 95% CI: 3.82–30.51, p = 0.001). Aortic regurgitation as the mechanism of prosthetic valve failure was associated with reduced PPI odds (OR 0.28, 95% CI: 0.10–0.76, p = 0.014). Pacing requirement—defined as > 90% ventricular pacing—increased from 25% at 3 months to 56.25% at 12 months. At a median follow‐up of 962.5 days (IQR 481.5–1555.3), adjusted mortality was significantly higher in the PPI group (aOR 9.4, 95% CI: 1.9–60.4, p = 0.028). Conclusion Bifascicular block, greater septal depth, and new bundle branch blocks predict PPI post‐ViV‐TAVR, while aortic regurgitation appears protective. Risk stratification and procedural planning are critical.
Safety of immunotherapy after liver transplantation—A multicenter study of a prospective standardized clinical practice protocol
Watt, Kymberly D. , Panda, Saurav , Pierluissi, Valeria , Abarca, Rachel, Rusch, D, Tapia, Amanda L. , Chascsa, David M. , Azhari, Hassan, Rusch, Danielle, Chascsa, David M , Panda, Saurav , Abou‐Alfa, Ghassan K.

Mayo Clinic

Liver Transplantation | October 13, 2025 | Volume: 32 | Issue: 5 | Pages: 685-692

10.1097/lvt.0000000000000749 | PMID 41082711 Get It

Immune checkpoint inhibitors (ICIs) have improved cancer prognosis significantly, but their use has been avoided in liver transplant recipients (LTr) due to poorly characterized rejection risk. Data surrounding rejection risk are extremely suboptimal, with highly variable immunosuppression approaches and follow-up, and do not account for the learning curve in managing immunosuppression in the setting of ICI. A standardized institutional clinical practice protocol was developed in 2021 for immunosuppression management to facilitate ICI therapy with prospective close follow-up for immunosuppression levels and allograft function. Of 20 LTr, 12 (60%) were male, 18 (90%) were Caucasian, with a mean age of 54.0 (SD 11.2) years. However, 13/20 had 2 or more failed cancer therapies before ICI. Hepatocellular carcinoma ​(HCC) (N=7), lung (N=3), and melanoma (N=3) were the most frequent. Time from first ICI treatment to death was <30 days (N=5), 30–59 days (N=4), 60–89 days (N=1), and >90 days (N=6). Most deaths were cancer-related, reflecting the late stage of disease. ICI toxicity occurred in 3 LTr; pneumonitis (N=1, 5%), myocarditis (N=1, 5%), and acute cellular rejection (N=1, 5%). Four patients remain alive 178–341 days with stable allograft function and slow reduction in immunosuppression. Three out of 4 patients have a partial cancer response, and 1 with slowed progression of disease. ICI treatment in the immunosuppressed LTr is feasible with careful immunosuppression management and follow-up. Demonstrating a low rejection risk should allow for earlier utilization of these agents to improve cancer prognosis. Optimizing rejection risk with cancer response requires ongoing study.
Association Between Thyroid Disease and Scleritis Using a Population-Based Method
Wang, Kenny Y. , Tanke, Laurel B. , Xu, Timothy T. , Liu, Liang-Yen L., Hodge, David O. , Smith, Wendy M. , Reynolds, Margaret

Mayo Clinic

Ocular Immunology and Inflammation | October 13, 2025 | Volume: 33 | Issue: 10 | Pages: 2408-2412

10.1080/09273948.2025.2573737 | PMID 41082311 Get It

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease
Lu, Ming , Collins, Emily C. , Shcherbinin, Sergey, Ellinwood, Amy K., Brooks, Dawn A. , Knopman, David S., Sims, John R. , Mintun, Mark A., Kim, Min Jung , Ellinwood, Amy K. , Yokoi, Yuma , Hansson, Oskar

Mayo Clinic

JAMA Neurology | October 13, 2025 | Volume: 82 | Issue: 12 | Pages: 1251

10.1001/jamaneurol.2025.3869 | PMID 41082199 Get It

Importance Accumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. Objective To assess the correlation of posttreatment amyloid levels with clinical outcomes and biomarkers in AD. Design, Setting, and Participants This was a post hoc exploratory analysis from the randomized, placebo-controlled phase 3 trial, TRAILBLAZER-ALZ 2, conducted June 2020 through April 2023 at 277 medical research centers/hospitals in 8 countries. A total of 8240 participants aged 60 to 85 years with early symptomatic AD with amyloid and tau pathology based on positron emission tomography (PET) imaging were assessed for eligibility. Of these, 6504 participants were excluded predominantly due to inadequate amyloid or tau pathology. The current analysis included 1582 participants (766 in the donanemab group and 816 in the placebo group) with baseline and at least 1 posttreatment assessment. Data analysis took place from July 2024 to March 2025. Interventions Participants were randomized 1:1 to receive donanemab (700 mg for the first 3 doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks, with outcomes assessed through 76 weeks. Main Outcomes and Measures Participants were categorized into 1 of 10 groups (deciles) based on their lowest amyloid value observed posttreatment. Clinical progression was assessed via changes in integrated Alzheimer’s Disease Rating Scale (iADRS) and Clinical Dementia Rating–Sum of Boxes (CDR-SB) scores. Plasma biomarkers measured included phosphorylated tau 217 (p-tau217), p-tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Correlations between the median amyloid level in each decile were assessed with 76-week least-squares mean changes in each outcome and biomarker. Results Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo. The mean (SD) age was 72.9 (6.2) years, and 900 participants (56.9%) were female. Participants who received donanemab had lower posttreatment amyloid values than those in the placebo group. Across the trial population, lower posttreatment amyloid levels were correlated with slower clinical progression as measured by iADRS score ( R 2 , 0.73 [95% CI, 0.37-0.97]) and CDR-SB score ( R 2 , 0.87 [95% CI, 0.70-0.97]) and with decreases in p-tau217 ( R 2 , 0.86 [95% CI, 0.73-0.97]), p-tau181 ( R 2 , 0.88 [95% CI, 0.77-0.97]), and GFAP ( R 2 , 0.87 [95% CI, 0.76-0.97]). There was no correlation between posttreatment amyloid value and NfL ( R 2 , 0.03 [95% CI, 0.00-0.54]). Conclusions and Relevance The findings in this secondary analysis of a randomized clinical trial demonstrating a correlation between posttreatment amyloid plaque level and clinical benefit support amyloid plaque removal as the mechanism of action for donanemab treatment and the level of amyloid plaque as a potential surrogate biomarker in amyloid-targeting therapies. Trial Registration ClinicalTrials.gov Identifier: NCT04437511
Biography of Louis Gaston Labat, M.D.
Brown, David L., Winnie, Alon P., Brown, David L.

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 17 | Issue: 5 | Pages: 249-262

10.1136/rapm-00115550-199217050-00002 Get It

2-Chloroprocaine and Bupivacaine Are Unreliable Indicators of Intravascular Injection in the Premedicated Patient
Mulroy, Michael F., Neal, Joseph M., Mackey, David C., Harrington, Brian E.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 11, 2025 | Volume: 23 | Issue: 1 | Pages: 9-13

10.1136/rapm-00115550-199823010-00004 Get It

Background and Objectives Epinephrine-containing test doses for detection of intravascular injection during epidural anesthesia may be unreliable or hazardous in beta-blocked, elderly, or pregnant patients. Subtoxic injections of lidocaine have been used as an alternative marker of intravascular injection in unpremedicated patients. We studied two groups of premedicated patients and unpremedicated subjects to evaluate the reliability of the local anesthetics bupivacaine (B) and 2-chloroprocaine (2-CP) as test dose injections. Methods Thirty ASA I and II subjects received blinded randomized injections of 2-CP, B, or normal saline via a peripheral vein. Results In group I, 10 healthy unpremedicated volunteers universally recognized injection of 90 mg 2-CP or 25 mg B, but did not reliably detect the injection of 60 mg 2-CP. In group II, 20 patients premedicated with 1 μg/kg fentanyl and 30 μg/kg midazolam could not reliably detect similar injections. Sixteen responded to the injection of 90 mg 2-CP, while 13 detected the 25 mg B test dose. A blinded observer rated only 12 of the subjective reports as conclusive of detection of intravascular injection after each drug. There were no false-positive reports in any group. Conclusions While 90 mg 2-CP or 25 mg B may be reliable alternatives to epinephrine test doses in unpremedicated subjects, they are unreliable indicators of intravascular injection in the premedicated patient.
Intramedullary Rodding of Impending Pathologic Fractures: Adverse Cardiopulmonary Events
Ducaji, J. S., Horlocker, Terese T. , Brown, David , Rock, Michael G., Schroeder, D. R.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 11, 2025 | Volume: 23 | Issue: Suppl 1 | Pages: 59-59

10.1136/rapm-00115550-199823031-00059 Get It

Sacroiliac Block of Therapeutic but Non Diagnostic Value
Shields, Sondra, Lamer, Tim J. , Marshall, Ken, Marshall, Ken, Mackey, David A.

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 20 | Issue: Suppl 2 | Pages: 16-16

10.1136/rapm-00115550-199520021-00016 Get It